Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 - Verona Pharma ( NASDAQ:VRNA )

2 weeks ago

One oral presentation and three posters support Ohtuvayre™ ( ensifentrine ) , as a first-in-class, selective, dual inhibitor of PDE3 and PDE4

Ticker	Sentiment	Impact
VRNA	Neutral	16 %